Lv2
200 积分 2024-02-04 加入
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2026 edition)]
1个月前
已完结
乳腺癌抗体药物偶联物不良反应管理指南（2025版）
1个月前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
4个月前
已完结
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis
4个月前
已完结
Impact of prior PARP inhibitor exposure on the efficacy of platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer: a propensity score-matched analysis
4个月前
已完结
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics
7个月前
已完结
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
8个月前
已完结
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
8个月前
已完结
Validation of the Mexican-Spanish Version of the EORTC QLQ-OV28 Instrument for the Assessment of Quality of Life in Women with Ovarian Cancer
8个月前
已完结
Ovarian cancer
8个月前
已完结
皖公网安备34019202002308
